Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Registration Number
- NCT00051974
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Brief Summary
The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.
- Detailed Description
In this study, patients with non-small cell lung cancer that is no longer responding to standard medical treatment with another anti-cancer drug will be randomly chosen to receive treatment with VELCADE alone or VELCADE in combination with docetaxel. Patients have almost equal chance of getting into either of the two treatment arms listed above.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 155
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (20)
Cedars-Sinai Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
UCLA Medical Center Thoracic Malignancy
🇺🇸Los Angeles, California, United States
Atlanta VAMC
🇺🇸Decatur, Georgia, United States
Washington University, Barnard Cancer Center
🇺🇸St. Louis, Missouri, United States
Univeristy of Florida Shands Cancer Center
🇺🇸Gainesville, Florida, United States
St. Louis University Health Sciences Center
🇺🇸St. Louis, Missouri, United States
University of Wisconsin Comprehensive Cancer Center
🇺🇸Madison, Wisconsin, United States
Vanderbilt University-Clinical Trials Center
🇺🇸Nashville, Tennessee, United States
University of Colorado Health Sciences Center
🇺🇸Aurora, Colorado, United States
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Hunstman Cancer Institute-University of Utah
🇺🇸Salt Lake City, Utah, United States
Mass. General Hospital Hem/Onc. Associates
🇺🇸Boston, Massachusetts, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
U of Alambama at Birmingham Comprehensive Cancer Center
🇺🇸Birmingham, Alabama, United States
Sylvester Comprehensive Cancer Center
🇺🇸Miami, Florida, United States
Winship Cancer Institute
🇺🇸Atlanta, Georgia, United States
DBA Kansas City Cancer Centers
🇺🇸Kansas City, Missouri, United States
Carolinas Hematology-Oncology Associates
🇺🇸Charlotte, North Carolina, United States
Kimmel Cancer Center at Jefferson
🇺🇸Philadelphia, Pennsylvania, United States
Yale University School Of Medicine
🇺🇸New Haven, Connecticut, United States